SARS-CoV-2/COVID-19 Natural Immunity

COVID-19 natural immunity is a controversial topic during the COVID-19 pandemic, perhaps because it conflicts with what appears to be a highly determined plan to mass vaccinate the world.

Research

T Cell Immunity

Both symptomatic and asymptomatic SARS-CoV-2 infections result in T cell responses, with greater interferon-\alpha producing responses from those with symptomatic infections.1)

Observational Studies

A group of scientists examined a wide swath of antibody data among Canadians during the first half of 2020 determining that more than 90% of uninfected adults showed preexisting antibody reactivity against SARS-CoV-2.2)

“SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021.” Gazit et al., August 2021.3)

Empirical Studies

Iliaki et al found zero reinfections in a study of urban health care workers.4)

Majdoubi, Michalski et al demonstrated the existence of cross-reactive antibodies as far back as May 2020, and concluded that more than 90% of uninfected adults showed antibody reactivity against the spike protein, receptor-binding domain (RBD), N-terminal domain (NTD), or the nucleocapsid (N) protein from SARS-CoV-2. This seroreactivity was evenly distributed across age and sex, correlated with circulating coronaviruses’ reactivity, and was partially outcompeted by soluble circulating coronaviruses’ spike.5)

Comparisons of Empirical Studies

Critique of Empirical Research

Vaccine natural immunity getting little study attention by public health authorities.6)

Research Summaries

https://childrenshealthdefense.org/defender/research-natural-immunity-covid-brownstone-institute/

Quick Listing of Supportive Articles/Publications to Share

Propaganda

CDC Propaganda

The Center for Disease Control and Prevention has abandoned all pretense that it is other than a government-funded public relations arm of the pharmaceutical industry during the pandemic. The topic of natural immunity makes this reality most plain.7)8)

1)
March 5, 2021 | Prasanna Jagannathan & Taia Wang | Nature Immunology | Immunity after SARS-CoV-2 infections | https://doi.org/10.1038/s41590-021-00923-3
2)
March 15, 2021 | Majdoubi et al | JCI Insight | A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2 | DOI:10.1172/jci.insight.146316
5)
Majdoubi, A., Michalski, C., O’Connell, S. E., Dada, S., Narpala, S. R., Gelinas, J. P., Mehta, D., Cheung, C., Winkler, D. F. H., Basappa, M., Liu, A. C., Görges, M., Barakauskas, V. E., Irvine, M. A., Mehalko, J., Esposito, D., Sekirov, I., Jassem, A. N., Goldfarb, D. M., & Pelech, S. (2021). A majority of uninfected adults show pre-existing antibody reactivity against SARS-CoV-2. JCI Insight. 2021;6(8):e146316. https://doi.org/10.1172/jci.insight.146316
Print/export